Compare GCBC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GCBC | ANL |
|---|---|---|
| Founded | 1889 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.1M | 611.1M |
| IPO Year | 1998 | 2022 |
| Metric | GCBC | ANL |
|---|---|---|
| Price | $33.56 | $12.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 43.9K | ★ 249.9K |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.97 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.25 | $0.88 |
| 52 Week High | $36.02 | $17.25 |
| Indicator | GCBC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 61.48 | 54.70 |
| Support Level | $31.52 | $11.86 |
| Resistance Level | $33.99 | $12.24 |
| Average True Range (ATR) | 1.20 | 1.14 |
| MACD | -0.23 | 0.31 |
| Stochastic Oscillator | 42.67 | 68.40 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.